KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Investments: 2017-2024

Historic Long-Term Investments for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $2.5 billion.

  • Moderna's Long-Term Investments fell 8.22% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 8.22%. This contributed to the annual value of $2.5 billion for FY2024, which is 46.68% down from last year.
  • Per Moderna's latest filing, its Long-Term Investments stood at $2.5 billion for FY2024, which was down 46.68% from $4.7 billion recorded in FY2023.
  • Moderna's 5-year Long-Term Investments high stood at $8.3 billion for FY2022, and its period low was $639.0 million during FY2020.
  • In the last 3 years, Moderna's Long-Term Investments had a median value of $4.7 billion in 2023 and averaged $5.2 billion.
  • In the last 5 years, Moderna's Long-Term Investments soared by 970.89% in 2021 and then tumbled by 46.68% in 2024.
  • Over the past 5 years, Moderna's Long-Term Investments (Yearly) stood at $639.0 million in 2020, then surged by 970.89% to $6.8 billion in 2021, then grew by 21.55% to $8.3 billion in 2022, then slumped by 43.77% to $4.7 billion in 2023, then tumbled by 46.68% to $2.5 billion in 2024.